Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label phase 1/2 study of ZN-d5 in relapsed or refractory AL amyloidosis
MOH_2022-05-01_010772Phase 2Active, not recruiting
- Sponsor
- K-Alpha
- Start
- Mar 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of asaretoclax in light-chain amyloidosis (2 arms), sponsored by K-Alpha. Primary endpoints: Safety and Preliminary efficacy. Started Mar 2022; status: active, not recruiting.
02
Drugs
asaretoclax
03
Conditions
light-chain amyloidosis
Beyond the preview
Go deeper on MOH_2022-05-01_010772.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2022-05-01_010772.